Cantor keeps USD 22.00 target for Omeros stock

Published on 10/15/2026 at 21:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 28.53 million versus USD 12.69 million consensus. Omeros stock costs EUR 16.85 on October 15, 2026 at Lang & Schwarz.

Cantor maintains target

Cantor Fitzgerald kept its USD 22.00 target for Omeros on October 14, 2026.
Second-quarter revenue reached USD 28.53 million against USD 12.69 million consensus.
Omeros stock traded at EUR 16.85 at 9:49 p.m. CEST at Lang & Schwarz on October 15, 2026.
Omeros had a P/E ratio of 10.93 as of October 15, 2026.

OMER, US6821431029, Illustration mit AI erstellt.

Cantor Fitzgerald maintained a Buy rating and a USD 22.00 price target for Omeros on October 14, 2026, according to Markets Insider. Against the USD 18.80 Nasdaq price at 3:56 p.m. ET on October 15, 2026, the target stood 17.02 percent higher. At Lang & Schwarz, Omeros stock was trading at EUR 16.85 on October 15, 2026 at 9:49 p.m. CEST.

Revenue beat remains central

Omeros reported USD 28.53 million in second-quarter revenue, compared with USD 12.69 million consensus. The company also reported adjusted earnings per share of USD 0.02 for the quarter, while the consensus estimate was a loss of USD 0.27, according to MarketBeat. The figures refer to the second quarter of 2026, reported on August 12, 2026.

The revenue comparison gives the analyst target a concrete operating backdrop. Revenue exceeded consensus by USD 15.84 million, while adjusted earnings per share exceeded the forecast by USD 0.29. The contrast matters because Omeros is moving from development spending toward commercial sales of its approved therapy.

Stock sits below yearly high

Omeros traded between a USD 6.24 52-week low and a USD 21.24 52-week high in the latest quoted range. The EUR 16.85 Lang & Schwarz price therefore sits below the USD-denominated high without a direct currency comparison. Its Nasdaq market capitalization was USD 1.4 billion on October 15, 2026, and the trailing P/E ratio was 10.93.

The latest Nasdaq quote showed Omeros at USD 18.80, up 2.01 percent from USD 18.43 at the previous close on October 15, 2026. That home-market move is separate from the euro quotation and does not change the Lang & Schwarz price used in this report.

Valuation and next milestones

The analyst target remains one of the clearest dated valuation markers for Omeros. Cantor Fitzgerald's USD 22.00 target was published on October 14, 2026, while the broader consensus cited by Markets Insider was USD 27.50. The consensus figure was based on analyst coverage and provides a wider reference point than the Cantor target.

Omeros is a Seattle-based biotechnology company focused on therapies for inflammatory and complement-mediated diseases. Its latest reported quarter included the commercial revenue comparison above, while the company continues to develop additional complement-pathway treatments. For investors, the key distinction is between the current commercial revenue base and the valuation assigned to future product expansion.

Market position in three figures

The stock's current picture combines a USD 1.4 billion market capitalization, a 10.93 P/E ratio and a USD 22.00 Cantor target. The valuation figures describe the Nasdaq listing, whereas the live German-market indication is EUR 16.85 at Lang & Schwarz. This separation is important when comparing a US biotechnology listing with its euro quotation.

Price and investor perspective

Omeros stock was trading at EUR 16.85 at Lang & Schwarz on October 15, 2026 at 9:49 p.m. CEST. The Nasdaq quote was USD 18.80 at 3:56 p.m. ET on the same date, with a 2.01 percent daily gain against USD 18.43.

The further course of trading is shown by the continuously updated real-time quote of Omeros stock.